NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection

Monday, August 27, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

HUBBARD, Ohio, Aug. 27 NanoLogix, Inc.(OTC: NNLX) is pleased to announce that Chris R. Novak, Esq. has joined thecompany as Director of Intellectual Property. In addition, we wish toannounce that major advances have been made in the rapid detection of Anthraxutilizing the NanoLogix BioNanoChannel(TM) Device.

Mr. Novak has over seven years' experience as an intellectual propertycounsel in a wide range of high tech industries including the position ofCorporate Intellectual Property Counsel of IDT (Integrated Device Technology,Inc.), a NASDAQ 100 semiconductor company with sales of over $800 million ayear. Mr. Novak has a Bachelor of Science in Mechanical Engineering and aJuris Doctorate, both awarded by Marquette University. He also holds a Masterof Science Degree in Electrical Engineering from Cal Poly State University.Mr. Novak is licensed for the practice of law in California, Colorado, andWisconsin and the United States Patent and Trademark Office (USPTO) and ispreparing for admission to the Ohio Bar. In addition to his experience as apatent attorney, Mr. Novak worked as an engineer for high-tech companies forten years.

"Mr. Novak will represent NanoLogix as our dedicated intellectual propertycounsel and manage the expansion and protection of our technologies throughpatents and other methods. NanoLogix's key asset value is its impressiveintellectual property portfolio," said Vice President of Strategic Partnering,Dana Allen. "We are pleased to welcome Chris to the Company in this newly-created role."

"I believe the revolutionary and practical ideas being developed atNanoLogix will have a major impact on the biotechnology and energy fields,"said Director of IP Chris Novak, Esq. "We plan to protect these ideas to thefullest extent, and turn these ideas into marketplace realities that willsharply increase revenues."

In another significant development, Nanologix has been working on arequest from the United States Department of Defense to explore the potentialof rapid determination of Anthrax spore viability, utilizing NanoLogix'sBioNanoChannel(TM) (BNC) technology. There appears to be an opportunity todetermine the viability and persistence of Anthrax spores much faster thancurrent methods due to the unique rapid culturing aspects of the BNCtechnology. "Superb progress has been made in our research efforts simulatingAnthrax spore growth through the use of non-hazardous spores. This researchhas the potential to immediately translate to the ability to conduct rapidAnthrax viability testing," said CEO Bret Barnhizer. "We have been impressedwith the Department of Defense's dedication to finding the best solution forthe security of our country in the event of a biological attack. We lookforward to making a major contribution in this area by providing a method bywhich the government is able to determine the effectiveness of theirdecontamination efforts in hours rather than days."

About NanoLogix, Inc.

NanoLogix is an industry innovator in the research, development, andcommercialization of nano-biotechnologies, applications and processes. TheCompany has developed and owns or has rights to 31 patents related to variousmedical technologies, 5 of which also have hydrogen-generation aspects. In thepast year the Company has filed an additional 28 patent applications fordiscoveries related to hydrogen bioreactors, medical testing, and innovativemedical treatments potentially related to leukemia and sepsis. NanoLogix ispresently operating a hydrogen bioreactor at Welch's Food. NanoLogix-developedpatents are used to design and market diagnostic test kits for use in earlydetection of the bacteria present in infectious and noninfectious humandiseases such as tuberculosis, pneumonia, HIV/AIDS, cancer, and cysticfibrosis. The company also owns a patent for the non-toxic induction ofapoptosis ('cell suicide') for the treatment of c

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store